Replies to post #214242 on Biotech Values

[MadCityCyclone]

saw that, cdxs is on fire too.

[jb_118]

TRIL, Any events causing the recent hike?

Nothing from their most recent conference call was worth moving the price at all. The only recent news I see is the addition of Dr. Helen Tayton-Martin to the BOD announced yesterday.

She's the CBO and co-founder of Adaptimmune. I don't know anything about her. Personally I think upward moves based on BOD additions are unwarranted.

Not sure if anything else caused the move.

TORONTO, Oct. 11, 2017 – Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, announced today that Dr. Helen Tayton-Martin has been appointed to its board of directors.

Dr. Tayton-Martin, Chief Business Officer at Adaptimmune, has over 25 years of experience working within the pharma, biotech and consulting environment in disciplines across preclinical and clinical development, outsourcing, strategic planning, due diligence and business development. She co-founded Adaptimmune from the former company, Avidex Limited, where she had been responsible for commercial development of the soluble TCR program in cancer and HIV therapy from 2005 to 2008. Dr. Tayton-Martin transitioned to become Adaptimmune's Chief Business Officer in March 2017, having served as its Chief Operating Officer since 2008, a role in which she oversaw the transition of all operations in the company from 5 to 300 staff, through transatlantic growth, multiple clinical, academic and commercial collaborations and private and public financing through to its NASDAQ IPO.

Today, Dr. Tayton-Martin is responsible for optimizing the strategic and commercial opportunity for Adaptimmune’s assets, leading business development and commercial activities. Her role encompasses all aspects of pipeline and technology assessment, strategic portfolio analysis, integrated program management and commercial planning and partnerships, including the company’s strategic partnership with GSK. Dr. Tayton-Martin holds a Ph.D. in molecular immunology from the University of Bristol, U.K. and an MBA from London Business School.

“We welcome Dr. Tayton-Martin to the Board of Trillium Therapeutics,” said Dr. Calvin Stiller, Trillium’s Chair. “Helen’s experience and involvement with a wide variety of operational and strategic activities in a rapidly growing life sciences company makes her addition to our board very opportune.”

http://trilliumtherapeutics.com/investors/news/Press-Release-Details/2017/Trillium-Therapeutics-Welcomes-Dr-Helen-Tayton-martin-to-Its-Board-of-Directors/default.aspx

[semi_infinite]

No idea whether it is just technical or whether there is something positive to be anticipated from upcoming readouts. Volume has been miniscule so volatility is to be expected.

[biocqr]

TRIL >TRILLIUM THERAPEUTICS’ TTI-621 PROGRAM FEATURED AT THE EORTC CLTF CUTANEOUS LYMPHOMA CONFERENCE

http://trilliumtherapeutics.com/investors/news/Press-Release-Details/2017/Trillium-Therapeutics-TTI-621-Program-Featured-at-the-EORTC-CLTF-Cutaneous-Lymphoma-Conference/default.aspx

Poster Presentation P-10: Synergistic Effect of Successive Administration of TTI-621 (SIRPaFc) and PEGylated Interferon-a2a in a Patient with Sézary Syndrome

Presenter: Dr. Oleg Akilov, University of Pittsburgh

This case study reported local and systemic anti-tumor activity in a Sézary syndrome patient treated with a single intratumoral dose of TTI-621. Administration of PEGylated Interferon-a2a seven days after TTI-621 resulted in decreased leukemic burden and improvements in clinical symptoms. Trillium believes such a reduction is not observed regularly with standard regimens and would not be anticipated following PEGylated Interferon-a2a monotherapy, suggesting a synergistic effect of TTI-621 and PEGylated Interferon-a2a.

“CTCL patients are being treated in both our intratumoral and intravenous trials,” said Dr. Niclas Stiernholm, Trillium’s Chief Executive Officer. “Careful study of the effects of TTI-621 in CTCL patients potentially provides us with a unique opportunity to better understand the mechanism behind TTI-621’s anti-tumor activity and the role of CD47 in the overall immuno-oncology landscape, ultimately leading to targeted indications and combination therapies with sound scientific rationale.”